07:46 AM EDT, 07/28/2025 (MT Newswires) -- ATAI Life Sciences ( ATAI ) shares were 10% lower pre-bell Monday after saying Friday that its phase 2b trial of inidascamine in patients with cognitive impairment associated with schizophrenia failed to achieve its primary endpoint.

Kazia Therapeutics ( KZIA ) stock was down 10% following a 1.4% loss in the previous session.

Linkhome Holdings ( LHAI ) shares were 9.3% lower, paring Friday's 83% rally.